November 17, 2014, 10:03 A.M. ET
Gilead: What About Its Pipeline?
By Ben Levisohn
UBS analyst Matthew Roden saying Gilead is undervalued, their pipeline optionality ranging from antivirals to fibrosis, solid tumors, and cardiovascular. We also think market is starting to underestimate Gilead’s commercial prowess despite an overall HCV package that is first and best in class.
was out of town Friday catching up and saw this on news feed. i will be getting in first thing Monday morning
One such company that is well positioned for future earnings growth is Gilead Sciences Inc. (
). This firm, is looking great for this year. In fact, the current growth estimate for this year calls for earnings-per-share growth of an impressive 312.8%. Furthermore, the long-term growth rate is currently 29.6%, suggesting pretty good prospects for the long haul.
Gilead Sciences (GILD) Harvoni Week 4 NRx Rises to 2768 - RBC Citing IMS LINKED
The Street Insider
Gilead Sciences (GILD) Harvoni Week 4 NRx Rises to 2768 - RBC Citing IMS
November 14, 2014 12:01 PM EST Gilead Sciences (NASDAQ: GILD) Harvoni week 4 TRx was 2865, accoring to RBC, citing IMS. NRx was 2768, up ...